Trial Profile
The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Compared to Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jan 2022
Price :
$35
*
At a glance
- Drugs Dulaglutide (Primary) ; Exenatide; Insulin glargine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AWARD-CHN2
- Sponsors Eli Lilly and Company
- 25 Sep 2020 Results (n=376) of post-hoc analysis assessing whether these two drugs showed different glucose-lowing effects in Chinese T2DM patients with varied baseline glycemic patterns presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 11 Jun 2019 Post hoc analysis results from AWARD-CHN1 and AWARD-CHN2 studies were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.